Last reviewed · How we verify
AER-271
At a glance
| Generic name | AER-271 |
|---|---|
| Sponsor | Aeromics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers (PHASE1)
- Phase 1 Study to Assess AER-271 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AER-271 CI brief — competitive landscape report
- AER-271 updates RSS · CI watch RSS
- Aeromics, Inc. portfolio CI